Inhibition of alveolar macrophage 5-lipoxygenase metabolism by auranofin
dc.contributor.author | Peters-Golden, Marc L. | en_US |
dc.contributor.author | Shelly, Candace | en_US |
dc.date.accessioned | 2006-04-07T20:49:08Z | |
dc.date.available | 2006-04-07T20:49:08Z | |
dc.date.issued | 1989-05-15 | en_US |
dc.identifier.citation | Peters-Golden, Marc, Shelly, Candace (1989/05/15)."Inhibition of alveolar macrophage 5-lipoxygenase metabolism by auranofin." Biochemical Pharmacology 38(10): 1589-1595. <http://hdl.handle.net/2027.42/27937> | en_US |
dc.identifier.uri | http://www.sciencedirect.com/science/article/B6T4P-4751SWR-1CP/2/b4596ad4d261eb05029429c0eb16c00c | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/27937 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=2499339&dopt=citation | en_US |
dc.description.abstract | We have examined the effect of the oral gold compound auranofin (AF) on calcium ionophore A23187-induced arachidonic acid metabolism in the rat alveolar macrophage. Both reverse-phase high performance liquid Chromatographie and radioimmunoassay analyses revealed that AF dose-dependently inhibited leukotriene B4 and 5-hydroxyeicosatetraenoic acid synthesis in a parallel fashion with an 50 ~ 4.3 [mu]g/ml. At the same time, AF augmented A23187-induced arachidonate release and cyclooxy-genase metabolism. A possible mechanism for the inhibition of 5-lipoxygenase was suggested by the capacity of AF to dose-dependently deplete ATP (50 ~ 5.9 [mu]g/ml), a cofactor for 5-lipoxygenase. These data indicate that, at therapeutic concentrations, AF acts in vitro as a selective inhibitor of macrophage 5-lipoxygenase metabolism. This likely represents an important mechanism of action of AF in chronic inflammatory disorders. | en_US |
dc.format.extent | 911930 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Elsevier | en_US |
dc.title | Inhibition of alveolar macrophage 5-lipoxygenase metabolism by auranofin | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Biological Chemistry | en_US |
dc.subject.hlbtoplevel | Science | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan and Veterans Administration Medical Centers, Ann Arbor, MI, U.S.A. | en_US |
dc.contributor.affiliationum | Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan and Veterans Administration Medical Centers, Ann Arbor, MI, U.S.A. | en_US |
dc.identifier.pmid | 2499339 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/27937/1/0000363.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1016/0006-2952(89)90306-7 | en_US |
dc.identifier.source | Biochemical Pharmacology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.